Intellia rapporterar starka fas iii-resultat för hae-behandling

12 maj 2026

Rapporterad av AI

Intellia Therapeutics presenterade huvudresultat från sin fas III-studie HALO gällande HAE under Bank of America Global Healthcare Conference den 12 maj. Resultaten visade på betydande kliniska fördelar för patienter med tillståndet.

Finansdirektör Edward Dulac beskrev resultaten som mycket uppmuntrande under sessionen. Alla patienter uppnådde en meningsfull klinisk nytta, där 62 procent förblev anfallsfria och terapifria vid slutet av den 28 veckor långa primära observationsperioden. Minskningen av anfallsfrekvensen nådde det höga 80-procentsintervallet, resultat som enligt Dulac matchar eller överträffar tidigare rapporter inom området.

Relaterade artiklar

Illustration of hemodialysis patient with fish oil supplements and PISCES trial graph showing 43% reduction in cardiovascular events.

High-dose fish oil linked to 43% fewer serious cardiovascular events in hemodialysis patients, trial reports

11 mars 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

A large international randomized trial found that 4 grams a day of omega-3 fish oil was associated with a 43% lower rate of serious cardiovascular events among adults receiving maintenance hemodialysis. The PISCES study enrolled 1,228 participants at 26 sites in Australia and Canada; results were presented at the American Society of Nephrology’s Kidney Week 2025 and published in The New England Journal of Medicine.

HLS Therapeutics releases Q4 2025 earnings call presentation

HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.

Syntara reports positive FDA feedback on amsulostat trial

30 april 2026 Rapporterad av AI

Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.

Hälsa

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Hälsa

Scientists call for multi-pronged strategies against Alzheimer's

Asien

Study reveals propolis potential for metabolic disorder patients

AI identifies breast cancer drug for multiple viruses

A repurposed breast cancer drug called MDL-001 has shown promise in lab and animal studies against a range of viruses, including flu, covid-19, RSV and norovirus. Developed by California-based Model Medicines using AI, the pill targets a conserved enzyme domain in viruses. A clinical trial is planned for early next year.

Stem cell therapy eases frailty in older adults

27 februari 2026 Rapporterad av AI

An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.

Gene therapy restores hearing in patients born deaf

A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.

12 maj 2026 21:13

Intellia rapporterar starka fas iii-resultat för hae-behandling

Relaterade artiklar

High-dose fish oil linked to 43% fewer serious cardiovascular events in hemodialysis patients, trial reports

HLS Therapeutics releases Q4 2025 earnings call presentation

Syntara reports positive FDA feedback on amsulostat trial

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Scientists call for multi-pronged strategies against Alzheimer's

Study reveals propolis potential for metabolic disorder patients

AI identifies breast cancer drug for multiple viruses

Stem cell therapy eases frailty in older adults

Gene therapy restores hearing in patients born deaf

Astrana Health CEO reports strong Q1 results at conference

Hims & Hers reports mixed first quarter results

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

How UC Boulder's Osteoarthritis Reversal Injection Could Transform Patient Lives

Isomorphic Labs’ AI-designed drugs advance to human trials

Animal studies show experimental injection reverses osteoarthritis

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

Alector stock jumps after BTIG upgrade

Evaxion reports improved 2025 financials and transformational clinical progress

Wireless PRIMA retinal implant improves central vision for many patients with advanced geographic atrophy, trial reports

Denna webbplats använder cookies